ANTIPARASITIC RESISTANCE: UPDATE ON THE PLANNED ACTIVITIES

Kuala Lumpur (Malaysia) 14-16 January 2020

Dr Mária Szabó

OIE AMR & Veterinary Products Department Paris, France



Outline

Currently no OIE standards or guidelines related to antiparasitic products

Feedback from the 4th and 5th cycle OIE Focal Point training seminars on veterinary products


Current situation based on the feedback received

Future Plan and Actions



Currently no OIE standards and guidelines on antiparasitic products

TrypanocidesSpecific Monograph



(slide from the previous seminars)



Feedback from the 4th and 5th Cycle of the OIE Focal Point training seminars

Antiparasitic drugs and challenges of antiparasitic resistance were first addressed at the 4th Cycle of the Seminar, in Entebbe, Uganda in 2015

Strong support received from the attendees that the OIE needs to consider publishing standards for antiparasitic drugs

This view was repeated during the OIE Regional Seminars for Veterinary Products for Asia (Tokyo, March 2016), Europe (Budapest, October 2016) and Middle East (Beirut, November 2017)

As a result: The subject of antiparasitic drugs and related challenges was included into the 5th Cycle training seminar in order to seek views in the interactive panel discussion



Feedback from the 4th and 5th Cycle of the OIE Focal Point training seminars

Interactive panel discussion intended to find answers for 2 main questions in the 5th Cycle:

Do we need OIE standards and guidelines on prudent and responsible use of antiparasitics?

Is it relevant for Africa, Asia, the Americas, Europe and the Middle East?



Feedback from the 5th Cycle of the OIE Focal Point training seminars

 All training seminars expressed a deep-rooted desire and interest working together to tackle the antiparasitic resistance



The latest seminar, which took place for the Region of Americas, from 1-3
August Tecámac (Mexico) 2018, concluded that urgent actions, led by the
OIE, should be considered.



Current situation

- There is a lack of effective drugs and resistance to many antiparasitics, especially to trypanocides, ascarides and anthelmintic resistance remain challenges to overcome
- There are many generic products which have been used for than 50 years, but not enough new 'quality' drugs available
- Poor quality products are on the markets, (substandard and falsified products); exposure of the sub-therapeutic doses, low concentration of active ingredient
- Antiparasitic drug residues in the environment (e.g. ivermectin and tolturazil)
- Residues in the food due to absence of appropriate withdrawal periods
- Lack of legislation for appropriate authorization of veterinary medicinal products in many countries



Current situation

There are some proposed strategies to delay or minimise the development of resistance were similar across drug product classes:

These strategies include ensuring

- accurate diagnosis, animal weights, and dosage
- proper label instructions for preparation and use of the product,
- selectively treating only animals that are clinically ill when possible,
- strategic use of antiparasitic drugs in an integrated parasite management plan when animals are at high risk for disease (e.g. young animals or high challenge).

Further, in some cases, animals that have innate resistance to the parasite species may be better suited in those geographic regions where the disease is prevalent (e.g. trypanotolerant breeds of cattle)

Multiple initiatives intended to monitor and address the problem of resistance were presented







Update from the field concerning antiparasitic resistance

Feedback from the 5th Cycle of the OIE Focal Point training seminars on veterinary products




http://www.oie.int/fileadmin/Home/eng/About_us/OIEnews/ NL-SEPT-2018-antiparasitic-resistance.pdf

FUTURE PLANS AND ACTIONS


- The 'Concept Note' was endorsed by the Hierarchy 2019
- The experts from different Regions will work on a publication on a Responsible and Prudent Use of Antiparasitics document which would be subject to endorsements by the OIE Director General and Scientific Commission for Animal Diseases (SCAD).
- The OIE, worked and will work closely
 its Collaborating Centers, and this subject will be lead by the Veterinary Medicine-Food and Drug
 Administration (CVM-FDA), who intends to continue this work

Future Plan and Actions









- FPs will be regularly informed on the progress made
- The publication could become the basis for the OIE Standards or Guideline(s) for prudent and responsible guideline for antiparasitics if warranted
- Consider a future issue of the Scientific and Technical Review dedicated to parasite management and antiparasitic resistance.



Thank you for your attention!



Dr Mária Szabó

Antimicrobial Resistance and Veterinary Products Department Paris, France

m.szabo@oie.int



WORLD ORGANISATION FOR ANIMAL HEALTH

Protecting animals, preserving our future

